当前位置：   首页 > 需求大厅

 >  特色服务 

需求名称：USP40或者39 palifermin质量标准（包括原液和制剂）。 具体要求：提供原文电子文件 完成时限：2017年5月5日   [更多]

需要的是阿立哌唑溶液剂的药典标准，是溶液剂的药典标准，！！！！！！不要原料药的标准。需查找美国、欧洲、日本的最新版本的药典，如没有收录请附目录证明。   [更多]

需要2016年至今尿毒清颗粒在山西各县市，零售销量。   [更多]

求购“Ranitidine Hydrochloride”《 BP2015 》的药典标准一份.   [更多]

本公司目前拥有种植基地，目前拥有多个品种种植的技术，现需要进行市场调研，寻求中药材市场流通信息： 1.最好是拥有全套产品的中药材市场供应信息 2.每一个中药材品种里面至少包含：产地、价格、产量、品质、下游应用厂家信息 3.具体品种可以私聊 4.价格面议   [更多]

和药品原厂说明书 属性一致，形成EXECL文档，一个药品一行，属性项就X轴排开，，   [更多]

本人由于研发需要，现想求购全套中药材生产基地信息，如果可以提供全套信息，价格面议，如果可以提供具体品种的中国种植基地信息，通过验证齐全且真实的，每个品种可以获得500元信息服务奖励   [更多]

1、P. A. Prajapati and M. M. Patel, “Formulation and in vitro evaluation of atropine sulphate viscous ocular solutions for the mydriatic and cycloplegic effect,” International Journal of Pharmaceutical and Applied Sciences, vol. 1, no. 2, pp. 70–78, 2010. View at Google Scholar 2、D. S. Satya, K. P. Suria, and P. P. Muthu, “Advanced approaches and evaluation of ocular drug delivery system,” American Journal of PharmTech Research, vol. 1, no. 4, pp. 72–92, 2011. View at Google Scholar 3、B. K. Nanjwade, D. B. Sonaje, and F. V. Manvi, “In vitro—in vivo release of ciprofloxacin from ophthalmic formulations,” International Journal of Pharmacy and Biotechnology, vol. 1, no. 1, pp. 23–28, 2011. View at Google Scholar 4、Physicochemical properties and stability of nicorandil By Nagai, Hiroshi; Koizumi, Ikue; Haneda, Masatoshi; Imai, Toshikatsu; Kikuchi, Mineo; Shiba, Motoharu From Iyakuhin Kenkyu (1983), 14(6), 968-79. Language: Japanese, Database: CAPLUS 5、Sobean oil partially hydrogenated 最新德国药典   [更多]

当心血管疾病（心脏病或中风）确诊后，医生会提供治疗建议，但病人的决定是至关重要的。美国心脏协会（AHA）与 以病人为中心的成果研究所（PCORI）合作，网络征集文章。你可以是患者，社区志愿者，家庭成员或任何人，只要你有这方面的亲身经验。根据你的情况来阐述患者的治疗决策是怎样做出的，例如：对寿命的影响，对生活质量的影响，费用，或其他？同时关心过程的完整性，时间，等等。。。 “请于2016年6月9日之前将稿件上传到：https://www.innocentive.com/ar/workspace/challengeDetail?challenge=9933835“ THE CHALLENGE Treatment of heart disease and stroke often requires patients and their families to make many decisions on how to move forward after a cardiac event. Specifically, AHA and PCORI are interested in learning about the “decisional dilemmas” you face – your insights will help guide future research to improve heart health. Based on the input from you and others in the patient and caregiver community, we will identify important concerns and use the perspectives to target research towards what matters most. Despite multiple available treatment options that your physician may describe, you may not always know which option is right/best for you. Tell us about the most difficult decision that you or your family faced when evaluating treatment options for heart disease or stroke. In addition, we would like to understand more about what you considered most important when making this choice or decision. Please pick your top three choices and tell us why they are important to you and your family: Side effects of the treatment Complexity of treatment plan Difficulty in adhering to a treatment Impact on my quality of life Potential to prolong my life Whether the best option for me is selected based on research of people similar to me (personal characteristics such as my age, race and gender) Whether my family history and genetic makeup would influence the effectiveness of a given option Whether a trusted source recommended a specific option The financial impact of the options for me and my family Other:________ Any submission should address the following Submission Requirements: The submission can be from anyone (patient, caregiver, family member, or other)   [更多]

防粘连产品属于三类医疗器械，现需行业终端销售数据、市场分布等信息。价格另议。   [更多]